Compare
Altimmune, Inc. vs HCW Biologics Inc. vs Clene Inc. vs Scienture Holdings, Inc.
| Latest fiscal year | Altimmune, Inc. ALT | HCW Biologics Inc. HCWB | Clene Inc. CLNN | Scienture Holdings, Inc. SCNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $41.0K | $54.2K | $200.0K | $431.6K |
| Revenue growth (YoY) | +105.0% | -97.9% | -41.5% | +215.9% |
| Gross margin | n/a | 20.0% | 78.5% (computed) | 76.8% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$88.09M | -$7.96M | -$26.17M | -$41.51M |
| EPS (Diluted) | -$1.00 | -$10.63 | n/a | -$2.70 |
| Operating cash flow | -$67.53M | -$13.39M | -$18.55M | -$13.38M |
| Free cash flow | -$67.55M | -$13.39M | -$18.59M | n/a |
| Cash & equivalents | $43.76M | $1.95M | $5.19M | $6.66M |
| Total assets | $279.93M | $24.52M | $18.13M | $84.18M |
| Total liabilities | $55.04M | $21.76M | $35.72M | $14.06M |
| Shareholders' equity | $224.89M | $2.76M | -$17.59M | $70.12M |
| Return on year-end equity | -39.2% | -287.9% | n/a | -59.2% |
| Shares outstanding | 110.88M | n/a | 10.85M | 40.63M |
Revenue, most recent five fiscal years
| Fiscal year | Altimmune, Inc. | HCW Biologics Inc. | Clene Inc. | Scienture Holdings, Inc. |
|---|---|---|---|---|
| Latest | $41.0K Ended 2025-12-31 | $54.2K Ended 2025-12-31 | $200.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 |
| 1 year earlier | $20.0K Ended 2024-12-31 | $2.57M Ended 2024-12-31 | $342.0K Ended 2024-12-31 | $136.6K Ended 2024-12-31 |
| 2 years earlier | $426.0K Ended 2023-12-31 | $2.84M Ended 2023-12-31 | $654.0K Ended 2023-12-31 | $1.36M Ended 2023-12-31 |
| 3 years earlier | -$68.0K Ended 2022-12-31 | $6.72M Ended 2022-12-31 | $473.0K Ended 2022-12-31 | $10.25M Ended 2022-12-31 |
| 4 years earlier | $4.41M Ended 2021-12-31 | $0 Ended 2021-12-31 | $723.0K Ended 2021-12-31 | $9.89M Ended 2021-12-31 |